New cancer combo shows early promise, but trial halted
NCT ID NCT05935098
First seen Apr 03, 2026 · Last updated May 21, 2026 · Updated 5 times
Summary
This early-phase study tested a new experimental drug, BGB-A3055, alone or with another drug (tislelizumab), in people with advanced solid tumors that had spread. The main goals were to check safety, how the body handles the drug, and whether it shrinks tumors. The study was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Advent Health Cancer Institute
Orlando, Florida, 32804-4603, United States
-
Asan Medical Center
SongpaGu, Seoul Teugbyeolsi, 05505, South Korea
-
Centre de Lutte Contre Le Cancer Institut Bergonie
Bordeaux, 33000, France
-
Changzhi Peoples Hospital
Changzhi, Shanxi, 046099, China
-
Chongqing University Cancer Hospital
Chongqing, Chongqing Municipality, 400030, China
-
Chris Obrien Lifehouse
Camperdown, New South Wales, 2050, Australia
-
Fred Hutchinson Cancer Research Center
Seattle, Washington, 98109-4433, United States
-
Fujian Cancer Hospital
Fuzhou, Fujian, 350014, China
-
Henan Cancer Hospital
Zhengzhou, Henan, 450000, China
-
Ico Site Rene Gauducheau
SaintHerblain, 44805, France
-
Icon Cancer Centre South Brisbane
South Brisbane, Queensland, 4101, Australia
-
Institut Curie
Paris, 75005, France
-
Jiangsu Province Hospital
Nanjing, Jiangsu, 210029, China
-
John Theurer Cancer Center Hackensack University Medical Center
Hackensack, New Jersey, 07601-2191, United States
-
Liaoning Cancer Hospital and Institute
Shenyang, Liaoning, 110042, China
-
Linear Clinical Research
Nedlands, Western Australia, 6009, Australia
-
Next Dallas
Irving, Texas, 75039-2743, United States
-
Rui Jin Hospital Shanghai Jiao Tong University School of Medicinejiading Branch
Shanghai, Shanghai Municipality, 201801, China
-
Samsung Medical Center
GangnamGu, Seoul Teugbyeolsi, 06351, South Korea
-
Seoul National University Bundang Hospital
BundangGu SeongnamSi, Gyeonggi-do, 13620, South Korea
-
Seoul National University Hospital
Seoul, Seoul Teugbyeolsi, 03080, South Korea
-
Severance Hospital Yonsei University Health System
SeodaemunGu, Seoul Teugbyeolsi, 03722, South Korea
-
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310003, China
-
The University of Texas Md Anderson Cancer Center
Houston, Texas, 77030-4009, United States
-
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, 300060, China
-
University of Iowa Hospitals and Clinics
Iowa City, Iowa, 52242-1009, United States
Conditions
Explore the condition pages connected to this study.